Immutep (IMMP) Total Liabilities (2011 - 2025)
Immutep's (IMMP) quarterly Total Liabilities came in at $31.7 million in Q4 2025, up 392.04% YoY from $6.4 million in Q4 2024, and up 270.99% on a QoQ basis from $8.5 million in Q2 2025.
Immutep (IMMP) Total Liabilities (2011 - 2025) Analysis & Trends
Immutep (IMMP) has 15 years of Total Liabilities data on file, last reported at $31.7 million in Q4 2025.
- Quarterly Total Liabilities rose 392.04% year-over-year to $31.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $31.7 million (up 392.04% YoY) and the FY2025 annual result came in at $8.5 million, up 7.58% from the prior year.
- Total Liabilities advanced to $31.7 million in Q4 2025, from $8.5 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $31.7 million in Q4 2025 to a low of $5.3 million in Q4 2023.
- A 5-year average of $9.4 million and a median of $7.0 million in 2021 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2021 — Total Liabilities retreated 28.47% — and 2025, when it jumped 392.04%.
- Tracing IMMP's Total Liabilities over 5 years: stood at $8.3 million in 2021, then decreased by 25.79% to $6.1 million in 2022, then retreated by 13.4% to $5.3 million in 2023, then climbed by 21.55% to $6.4 million in 2024, then jumped by 392.04% to $31.7 million in 2025.
- The last three Total Liabilities figures came in at $31.7 million (Q4 2025), $8.5 million (Q2 2025), and $6.4 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 10.03 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 3.22 Bn |
| 10 | Immutep | 57.14 Mn | -7.95 Mn | - | 31.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 31.71 Mn |
| Jun 30, 2025 | 8.55 Mn |
| Dec 31, 2024 | 6.45 Mn |
| Jun 30, 2024 | 7.95 Mn |
| Dec 31, 2023 | 5.30 Mn |
| Jun 30, 2023 | 7.34 Mn |
| Dec 31, 2022 | 6.12 Mn |
| Jun 30, 2022 | 5.80 Mn |
| Dec 31, 2021 | 8.25 Mn |
| Jun 30, 2021 | 6.74 Mn |
| Dec 31, 2020 | 11.54 Mn |
| Jun 30, 2020 | 8.72 Mn |
| Dec 31, 2019 | 10.20 Mn |
| Jun 30, 2019 | 11.32 Mn |
| Dec 31, 2018 | 10.55 Mn |
| Jun 30, 2018 | 10.20 Mn |
| Jun 30, 2017 | 6.33 Mn |
| Mar 31, 2017 | 5.22 Mn |
| Dec 31, 2016 | 28.63 Mn |
| Jun 30, 2016 | 5.40 Mn |